FDA-cleared profile

SubtleHD-CT (1.x)

Subtle Medical, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Process and enhance CT images from any CT scanner manufacturer or model as an adjunct to the original reconstructed image.

Clinical role
Background post-processing image enhancement with adjunctive radiologist review.
Images and patients
CT/CTA · Multiple CT anatomies: abdomen, C-spine, cardiac, chest, chest-abdomen-pelvis, head, head/neck, L-spine, lower extremity, MSK, T-spine, and upper extremity.
Key limitation
Keep in mind: Output interpretation is adjunctive to the original reconstructed image. Use with iterative reconstruction or deep-learning reconstructions may have unknown performance; advanced third-party post-processing or specialized non-standard filtering was not specifically characterized, and direct primary scanner reconstructions are recommended.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Process and enhance CT images from any CT scanner manufacturer or model as an adjunct to the original reconstructed image.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multiple CT anatomies: abdomen, C-spine, cardiac, chest, chest-abdomen-pelvis, head, head/neck, L-spine, lower extremity, MSK, T-spine, and upper extremity. Input: Primary reconstructed DICOM CT images sent by a technologist through a compatible MDDS; FBP primary reconstructions at standard or higher dose were quantitatively validated. The packet also includes varied scanners, anatomies, contrast, reconstruction methods, and slice thicknesses, but warns that IR/DL reconstruction performance may be unknown.
  • Who uses it?Intended users: Radiologists.
  • What does the software produce?Output: Enhanced DICOM CT images returned through the compatible MDDS to PACS or another DICOM node; enhanced images coexist with the original reconstructed images; no user interface.
  • What is its most important limitation?Key limitation: Output interpretation is adjunctive to the original reconstructed image. Use with iterative reconstruction or deep-learning reconstructions may have unknown performance; advanced third-party post-processing or specialized non-standard filtering was not specifically characterized, and direct primary scanner reconstructions are recommended.

Clinical takeaway. Clinical role: Process and enhance CT images from any CT scanner manufacturer or model as an adjunct to the original reconstructed image.

Evidence takeaway. Evidence from the reviewed source record: FDA K254120 reports phantom performance validation using ACR, Digital CatPhan 600, and Mercury 4.0 phantoms plus a 270-case retrospective reader study. Phantom endpoints included detectability index, noise magnitude, NPS, CT-number accuracy, non-uniformity, and TTF, all reported as passing their stated criteria. Reader endpoints were diagnostic utility (average Likert score >=3) and artifact presence (average score >=2); no sensitivity/specificity or disease-detection accuracy was reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Process and enhance CT images from any CT scanner manufacturer or model as an adjunct to the original reconstructed image.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Background post-processing image enhancement with adjunctive radiologist review.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Primary reconstructed DICOM CT images sent by a technologist through a compatible MDDS; FBP primary reconstructions at standard or higher dose were quantitatively validated. The packet also includes varied scanners, anatomies, contrast, reconstruction methods, and slice thicknesses, but warns that IR/DL reconstruction performance may be unknown.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Enhanced DICOM CT images returned through the compatible MDDS to PACS or another DICOM node; enhanced images coexist with the original reconstructed images; no user interface.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Medical facilities including hospitals, clinics, and imaging centers; the reader dataset included adult and pediatric subjects.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Output interpretation is adjunctive to the original reconstructed image. Use with iterative reconstruction or deep-learning reconstructions may have unknown performance; advanced third-party post-processing or specialized non-standard filtering was not specifically characterized, and direct primary scanner reconstructions are recommended.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K254120 reports phantom performance validation using ACR, Digital CatPhan 600, and Mercury 4.0 phantoms plus a 270-case retrospective reader study. Phantom endpoints included detectability index, noise magnitude, NPS, CT-number accuracy, non-uniformity, and TTF, all reported as passing their stated criteria. Reader endpoints were diagnostic utility (average Likert score >=3) and artifact presence (average score >=2); no sensitivity/specificity or disease-detection accuracy was reported.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K254120 reports phantom performance validation using ACR, Digital CatPhan 600, and Mercury 4.0 phantoms plus a 270-case retrospective reader study. Phantom endpoints included detectability index, noise magnitude, NPS, CT-number accuracy, non-uniformity, and TTF, all reported as passing their stated criteria. Reader endpoints were diagnostic utility (average Likert score >=3) and artifact presence (average score >=2); no sensitivity/specificity or disease-detection accuracy was reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

SubtleHD-CT (1.x) regulatory performance study summary

  • DesignReader Study
  • PopulationAdult and Pediatric
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K254120
  • IndependenceIndependence not established

K254120

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K254120. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Primary reconstructed DICOM CT images sent by a technologist through a compatible MDDS; FBP primary reconstructions at standard or higher dose were quantitatively validated. The packet also includes varied scanners, anatomies, contrast, reconstruction methods, and slice thicknesses, but warns that IR/DL reconstruction performance may be unknown.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K254120: SubtleHD-CT (1.x)

  2. Routing

    Source context, not route validation: Technologist routes the study from the CT scanner to a compatible MDDS via DICOM; the MDDS supplies images to SubtleHD-CT and returns enhanced images to PACS or another DICOM node using an AE Title.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K254120: SubtleHD-CT (1.x)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Enhanced DICOM CT images returned through the compatible MDDS to PACS or another DICOM node; enhanced images coexist with the original reconstructed images; no user interface.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K254120: SubtleHD-CT (1.x)

  5. Viewer/worklist/report

    Unresolved route: Enhanced DICOM CT images returned through the compatible MDDS to PACS or another DICOM node; enhanced images coexist with the original reconstructed images; no user interface.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K254120: SubtleHD-CT (1.x)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Technologist routes the study from the CT scanner to a compatible MDDS via DICOM; the MDDS supplies images to SubtleHD-CT and returns enhanced images to PACS or another DICOM node using an AE Title.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for SubtleHD-CT (1.x); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K254120
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Multiple CT anatomies: abdomen, C-spine, cardiac, chest, chest-abdomen-pelvis, head, head/neck, L-spine, lower extremity, MSK, T-spine, and upper extremity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, vendor product page, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K254120 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K254120: SubtleHD-CT (1.x)

    U.S. Food and Drug Administration - Published 2026-05-15 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SubtleHD-CT (1.x) model card (K254120)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K254120

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Subtle Medical Compliance

    Subtle Medical, Inc. - Accessed 2026-10-25

    Scope: security

Research history

  1. K254120 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K242624

Medical Image Post-processing Software (uOmnispace.CT)

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.

Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Decision
2025-05-14
FDA-cleared K233209

uOmnispace.CT

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uOmnispace.CT is software for viewing, manipulating, evaluating, and analyzing medical images within healthcare institutions. The FDA indication lists colon visualization, dental panoramic and paraxial reconstruction, lung and airway segmentation and quantitative parameters, nodule analysis, vessel and brain-perfusion analysis, heart and coronary analysis, calcium scoring, dynamic analysis, bone-structure labeling, liver evaluation, dual-energy processing, and cardiovascular combined analysis.

Modality
CT/CTA
Anatomy
Colon, jaw, lungs, airways, brain, heart, vessels, liver, spine, ribs, and other labeled CT regions
Decision
2024-05-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history